Survival in untreated early stage non-small cell lung cancer

Amandeep S. Chadha, Apar Kishor P Ganti, Jaideep S. Sohi, Abe E. Sahmoun, Syed A. Mehdi

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Background: The aim of this study was to determine the survival of untreated stage I and II in non-small cell lung cancer (NSCLC) patients. Patients and Methods: A retrospective analysis of medical charts of all patients diagnosed with early stage NSCLC, between January 1990 and December 2001, was conducted and patients who were not treated were identified. Data on patient's age, gender, stage of the disease, pathology, reason for non-treatment and cause of death were reviewed. Results: Thirty-nine patients with untreated stage I and II NSCLC were identified. The median age at diagnosis was 77 years; 66.7% were men and 33.3% were women. All patients were Caucasian and 66.7% had stage I disease, 46.2% had squamous cell carcinoma, while adenocarcinoma was found in 28.2%. The major reason for non treatment was chronic obstructive pulmonary disease (64.1%) and the main cause of death was metastatic disease (48.7%). The overall mean survival was 11.9 months. The mean survival at stage I was not statistically different from the mean survival at stage II (13.7months vs. 8.4 months) (p<0.12). Conclusion: Patients with untreated early stages NSCLC have a very poor prognosis. Alternative therapies that are better tolerated should be investigated in these patients with early stage NSCLC who cannot be offered standard treatment.

Original languageEnglish (US)
Pages (from-to)3517-3520
Number of pages4
JournalAnticancer Research
Volume25
Issue number5
StatePublished - Sep 1 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Cause of Death
Complementary Therapies
Chronic Obstructive Pulmonary Disease
Squamous Cell Carcinoma
Adenocarcinoma
Pathology
Therapeutics

Keywords

  • Lung cancer
  • Prognosis
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chadha, A. S., Ganti, A. K. P., Sohi, J. S., Sahmoun, A. E., & Mehdi, S. A. (2005). Survival in untreated early stage non-small cell lung cancer. Anticancer Research, 25(5), 3517-3520.

Survival in untreated early stage non-small cell lung cancer. / Chadha, Amandeep S.; Ganti, Apar Kishor P; Sohi, Jaideep S.; Sahmoun, Abe E.; Mehdi, Syed A.

In: Anticancer Research, Vol. 25, No. 5, 01.09.2005, p. 3517-3520.

Research output: Contribution to journalReview article

Chadha, AS, Ganti, AKP, Sohi, JS, Sahmoun, AE & Mehdi, SA 2005, 'Survival in untreated early stage non-small cell lung cancer', Anticancer Research, vol. 25, no. 5, pp. 3517-3520.
Chadha AS, Ganti AKP, Sohi JS, Sahmoun AE, Mehdi SA. Survival in untreated early stage non-small cell lung cancer. Anticancer Research. 2005 Sep 1;25(5):3517-3520.
Chadha, Amandeep S. ; Ganti, Apar Kishor P ; Sohi, Jaideep S. ; Sahmoun, Abe E. ; Mehdi, Syed A. / Survival in untreated early stage non-small cell lung cancer. In: Anticancer Research. 2005 ; Vol. 25, No. 5. pp. 3517-3520.
@article{8f694772ec7540388ad3292b364be412,
title = "Survival in untreated early stage non-small cell lung cancer",
abstract = "Background: The aim of this study was to determine the survival of untreated stage I and II in non-small cell lung cancer (NSCLC) patients. Patients and Methods: A retrospective analysis of medical charts of all patients diagnosed with early stage NSCLC, between January 1990 and December 2001, was conducted and patients who were not treated were identified. Data on patient's age, gender, stage of the disease, pathology, reason for non-treatment and cause of death were reviewed. Results: Thirty-nine patients with untreated stage I and II NSCLC were identified. The median age at diagnosis was 77 years; 66.7{\%} were men and 33.3{\%} were women. All patients were Caucasian and 66.7{\%} had stage I disease, 46.2{\%} had squamous cell carcinoma, while adenocarcinoma was found in 28.2{\%}. The major reason for non treatment was chronic obstructive pulmonary disease (64.1{\%}) and the main cause of death was metastatic disease (48.7{\%}). The overall mean survival was 11.9 months. The mean survival at stage I was not statistically different from the mean survival at stage II (13.7months vs. 8.4 months) (p<0.12). Conclusion: Patients with untreated early stages NSCLC have a very poor prognosis. Alternative therapies that are better tolerated should be investigated in these patients with early stage NSCLC who cannot be offered standard treatment.",
keywords = "Lung cancer, Prognosis, Survival",
author = "Chadha, {Amandeep S.} and Ganti, {Apar Kishor P} and Sohi, {Jaideep S.} and Sahmoun, {Abe E.} and Mehdi, {Syed A.}",
year = "2005",
month = "9",
day = "1",
language = "English (US)",
volume = "25",
pages = "3517--3520",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Survival in untreated early stage non-small cell lung cancer

AU - Chadha, Amandeep S.

AU - Ganti, Apar Kishor P

AU - Sohi, Jaideep S.

AU - Sahmoun, Abe E.

AU - Mehdi, Syed A.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Background: The aim of this study was to determine the survival of untreated stage I and II in non-small cell lung cancer (NSCLC) patients. Patients and Methods: A retrospective analysis of medical charts of all patients diagnosed with early stage NSCLC, between January 1990 and December 2001, was conducted and patients who were not treated were identified. Data on patient's age, gender, stage of the disease, pathology, reason for non-treatment and cause of death were reviewed. Results: Thirty-nine patients with untreated stage I and II NSCLC were identified. The median age at diagnosis was 77 years; 66.7% were men and 33.3% were women. All patients were Caucasian and 66.7% had stage I disease, 46.2% had squamous cell carcinoma, while adenocarcinoma was found in 28.2%. The major reason for non treatment was chronic obstructive pulmonary disease (64.1%) and the main cause of death was metastatic disease (48.7%). The overall mean survival was 11.9 months. The mean survival at stage I was not statistically different from the mean survival at stage II (13.7months vs. 8.4 months) (p<0.12). Conclusion: Patients with untreated early stages NSCLC have a very poor prognosis. Alternative therapies that are better tolerated should be investigated in these patients with early stage NSCLC who cannot be offered standard treatment.

AB - Background: The aim of this study was to determine the survival of untreated stage I and II in non-small cell lung cancer (NSCLC) patients. Patients and Methods: A retrospective analysis of medical charts of all patients diagnosed with early stage NSCLC, between January 1990 and December 2001, was conducted and patients who were not treated were identified. Data on patient's age, gender, stage of the disease, pathology, reason for non-treatment and cause of death were reviewed. Results: Thirty-nine patients with untreated stage I and II NSCLC were identified. The median age at diagnosis was 77 years; 66.7% were men and 33.3% were women. All patients were Caucasian and 66.7% had stage I disease, 46.2% had squamous cell carcinoma, while adenocarcinoma was found in 28.2%. The major reason for non treatment was chronic obstructive pulmonary disease (64.1%) and the main cause of death was metastatic disease (48.7%). The overall mean survival was 11.9 months. The mean survival at stage I was not statistically different from the mean survival at stage II (13.7months vs. 8.4 months) (p<0.12). Conclusion: Patients with untreated early stages NSCLC have a very poor prognosis. Alternative therapies that are better tolerated should be investigated in these patients with early stage NSCLC who cannot be offered standard treatment.

KW - Lung cancer

KW - Prognosis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=23344431782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23344431782&partnerID=8YFLogxK

M3 - Review article

C2 - 16101172

AN - SCOPUS:23344431782

VL - 25

SP - 3517

EP - 3520

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -